A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
Keywords:
Coltuximab ravtansine
Anti-CD19 antibody drug conjugate
SAR3419
Diffuse large B-cell lymphoma
Editorial note:
© 2023 by the Ferrata Storti
Citation:
Canales-Albendea, M. A. (Miguel Ángel); Trneny, M. (Marek); Verhoef, G. (Gregor); et al. "A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy". Haematologica. 103 (8), 2018, 1351 - 1358
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.